Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cathy Kelly

Senior Writer

Washington, DC
Cathy Kelly has been covering reimbursement and market access news for more than a decade for "The Pink Sheet" and other publications that are now part of Informa's pharmaceutical intelligence resources. Her expertise spans legislative, regulatory and public policy topics as well as coverage trends in public and private insurance markets. Cathy is especially interested in following the ongoing transformation of the US health care system and its effect upon major stakeholders in the biopharma industry. She is based in Washington D.C.
Advertisement
Set Alert for Articles By Cathy Kelly

Latest From Cathy Kelly

Gilead Lowering HCV Drug List Prices With Authorized Generics

Approach has been endorsed by Express Scripts as more workable solution than trying to cut list prices for drugs already on the market.

Pricing Debate Pricing Strategies

PBM Trade Group Taps Medical Device Lobbyist Scott As CEO

AdvaMed Chief Advocacy Officer JC Scott will take the reins at PCMA in mid-October.

Pharmacy Benefit Management Leadership

PCMA’s Merritt Reflects On 15 Years At The Helm Of PBM Advocacy

Outgoing Pharmaceutical Care Management Association chief discusses fight over rebates, future of pharmacy benefit management, opportunities and challenges facing his successor.

Pharmacy Benefit Management Policy

Medicare Part D ‘Modernization’ Policies Still Priority Reforms – OMB’s Grogan

Office of Management and Budget health programs official highlights the Administration’s plan for updating and lowering costs in Medicare Part D, including point-of-sale rebates.

Pricing Debate Regulation

DTC Ad Price Disclosure Provision Stripped From US Funding Bill

Even though measure was blocked in Congress, it may still advance through regulation.

Pricing Debate Advertising, Marketing & Sales

Drug Pricing Critic Peter Bach Named Chair Of Medicare Advisory Panel

But appointment unlikely to signal new emphasis on prescription drugs for MedCAC.

Medicare Regulation
See All
Advertisement
UsernamePublicRestriction

Register